Crte7A2-01 Tcr-T Cell
Head and Neck Cancers
Corregene Biotechnology Co., LtdCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
141 Active assets in the Head and Neck Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Instituto Nacional de Cancer, Brazil | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II ImmunityBio, Inc. | Phase 3 | BB |
LIDOCAINE Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
FILGRASTIM University of Colorado, Denver | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Crte7A2-01 Tcr-T Cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →